Tongkat Ali

Metadata

Approved Indications

Commission E / ESCOP / EMA/HMPC

Tongkat Ali has not been assessed by any of the three major European phytotherapy regulatory bodies:

• Commission E (Germany): No monograph exists. Eurycoma longifolia is not part of the European herbal tradition evaluated by Commission E. The plant is native to Southeast Asia and was virtually unknown in European phytotherapy at the time of Commission E’s active period (1978-1994).
• ESCOP (European Scientific Cooperative on Phytotherapy): No monograph. The herb falls outside the scope of traditional European phytotherapy plants covered by ESCOP.
• EMA/HMPC (European Medicines Agency / Committee on Herbal Medicinal Products): No assessment report or monograph. Eurycoma longifolia is not listed in the EU herbal substances inventory for medicinal use. However, the EFSA (European Food Safety Authority) Panel on Nutrition, Novel Foods and Food Allergens published a safety assessment in 2021 for the standardized water extract as a novel food ingredient, concluding that the applicant had not demonstrated safety for the proposed uses and conditions due to potential genotoxicity concerns at high doses (2,000 mg/kg body weight in animal models).

This regulatory gap reflects the geographic and cultural origin of the herb rather than a negative safety or efficacy assessment. Tongkat Ali originates from the Southeast Asian ethnobotanical tradition and has only recently entered the global supplement market in significant quantities.

Malaysian and Southeast Asian Regulatory Status

• Malaysia: Eurycoma longifolia is approved as a traditional medicine by the Malaysian Ministry of Health (National Pharmaceutical Regulatory Agency). The root extract is listed as a recognized traditional ingredient and is one of Malaysia’s most commercially important medicinal plants. The Malaysian Standard MS 2409:2011 specifies quality requirements for Eurycoma longifolia water extract.
• Indonesia: Known as Pasak Bumi, the herb is recognized within the traditional medicine (Jamu) system and is approved for use in traditional herbal products by BPOM (Indonesian National Agency of Drug and Food Control).
• United States: Available as a dietary supplement under DSHEA. No FDA GRAS notice has been issued; the herb is sold as a supplement, not a food ingredient.
• Australia: Listed on the Australian Register of Therapeutic Goods (ARTG) as a permitted ingredient in listed medicines.

Agreement/Disagreement Analysis

Since no European regulatory monographs exist, there is no formal European consensus to analyze. The significant gap between the growing clinical evidence base (multiple RCTs, a 2022 systematic review and meta-analysis) and the absence of any European regulatory recognition reflects the slow integration of non-European traditional medicines into European regulatory frameworks. The Malaysian regulatory approval and standardization efforts (MS 2409:2011) provide the most robust regulatory anchor for this herb. The 2021 EFSA novel food safety assessment raised concerns about potential DNA damage at very high doses in animal models, but this involved doses far exceeding the typical human supplemental range and used different endpoints than the clinical trials demonstrating safety at 200-400 mg/day.

Conditions Treated

Primary (Moderate Evidence)

• Testosterone support in aging and hypogonadal men — The most clinically substantiated indication. A 2022 systematic review and meta-analysis (Leisegang et al.) of five RCTs found a statistically significant increase in total testosterone levels following Eurycoma longifolia supplementation. The Chinnappan et al. (2021) multicentre RCT demonstrated significant total testosterone increases at 200 mg/day Physta within 2-4 weeks in men aged 50-70 with baseline testosterone below 300 ng/dL. The effect appears to involve SHBG modulation and HPA axis recalibration rather than direct testicular stimulation.

• Stress adaptation and cortisol-testosterone ratio modulation — Talbott et al. (2013) demonstrated a 16% reduction in salivary cortisol and a 37% increase in salivary testosterone in moderately stressed subjects (n=63) after 4 weeks of 200 mg/day supplementation with standardized extract. The improvement in the cortisol-to-testosterone ratio is considered a clinically meaningful marker of stress adaptation and has implications for well-being, body composition, and recovery.

Secondary (Preliminary Evidence)

• Ergogenic and sports performance effects — Henkel et al. (2014) found significant increases in total and free testosterone concentrations and muscular force in physically active male and female seniors (n=25, 57-72 years) supplemented with 400 mg/day for 5 weeks. However, a 2024 study by Escalante et al. found that 400 mg/day for 4 weeks did not significantly affect body composition (lean mass, fat mass, body weight) in exercise-trained males and females (n=33). The ergogenic evidence is therefore mixed, with positive signals for hormonal and strength outcomes but not consistently for body composition.

• Sexual function and erectile function — Ismail et al. (2012) demonstrated improved physical functioning scores and sexual well-being (IIEF, Sexual Health Questionnaire) in 109 men aged 30-55 given 300 mg/day Physta for 12 weeks. Udani et al. (2014) reported improved erectile function and sexual well-being. A 6-month RCT by Sazali et al. (2021) showed that 200 mg/day Eurycoma longifolia combined with concurrent training significantly improved erectile function (IIEF-5 scores) in men with androgen deficiency of aging males (ADAM).

• Age-related hormonal decline (late-onset hypogonadism) — An open-label study by Tambi et al. (2012) in 76 men with late-onset hypogonadism (LOH) showed that 200 mg/day water extract for one month significantly decreased the Aging Males’ Symptoms (AMS) score and increased serum testosterone levels, with 90.8% of patients showing normal testosterone values after treatment compared to 35.5% at baseline. While this was an open-label study (lower evidence quality), the effect size was notable.

Traditional Uses (Malaysian/Indonesian Ethnomedicine)

In traditional Southeast Asian medicine, Eurycoma longifolia root decoctions have been used for a wide range of conditions, documented over centuries of use in the Malay Peninsula, Borneo, Sumatra, and Indochina:

• Aphrodisiac and male virility — The most prominent traditional use; the name “Tongkat Ali” literally translates to “Ali’s walking stick” (a euphemism for male potency). Root decoctions were consumed to enhance sexual desire and performance.
• Intermittent fever and malaria — Quassinoid-containing root preparations were widely used as an antimalarial remedy. The quassinoids eurycomanone and 13-alpha(21)-epoxyeurycomanone have demonstrated in vitro antimalarial activity against Plasmodium falciparum.
• General tonic and vitality — Used as a post-illness recuperative tonic and as a general adaptogen to combat fatigue, weakness, and lethargy.
• Fever, dysentery, and diarrhea — Root and bark decoctions were used for gastrointestinal complaints and febrile illnesses.
• Bone pain, rheumatism, and glandular swelling — Topical and oral preparations for musculoskeletal and inflammatory conditions.
• Postpartum recovery — Used by women in some traditions for restoration after childbirth, though modern use focuses predominantly on male health.

Mechanism of Action

Primary Mechanism: Eurypeptide-Mediated SHBG Modulation and HPA Axis Recalibration

The dominant mechanistic hypothesis for Tongkat Ali’s effects on testosterone parameters centers not on direct androgenic stimulation or gonadotropin release, but rather on two complementary pathways:

1. Sex hormone-binding globulin (SHBG) reduction and free testosterone liberation: Bioactive peptides isolated from Eurycoma longifolia root, collectively termed “eurypeptides” (polypeptides of approximately 36 amino acids in the 4.3 kDa molecular weight range), appear to reduce SHBG binding affinity for testosterone. SHBG normally binds approximately 60-70% of circulating testosterone, rendering it biologically inactive. By reducing SHBG-testosterone binding, eurypeptides increase the fraction of free (bioavailable) testosterone without necessarily increasing total testosterone production. Chan et al. (2021) found that in young healthy males, 600 mg/day for 2 weeks produced a 15% increase in total testosterone and a 34% increase in free testosterone, while LH, FSH, and SHBG levels themselves did not change significantly — supporting a mechanism involving altered binding dynamics rather than increased production or gonadotropin stimulation.

2. Hypothalamic-pituitary-adrenal (HPA) axis modulation and cortisol reduction: Talbott et al. (2013) demonstrated that Tongkat Ali supplementation significantly reduced salivary cortisol (-16%) while increasing salivary testosterone (+37%) in moderately stressed subjects. Chronic stress elevates cortisol through sustained HPA axis activation, which in turn suppresses the hypothalamic-pituitary-gonadal (HPG) axis and reduces testosterone production. By reducing cortisol output or improving cortisol clearance, Tongkat Ali may indirectly restore testosterone levels by relieving the cortisol-mediated suppression of the HPG axis. This “stress-shielding” mechanism is consistent with the herb’s traditional use as a recuperative tonic and may explain why effects are more pronounced in stressed or hormonally compromised populations.

Secondary Mechanisms

3. Quassinoid-mediated effects on steroidogenesis (eurycomanone): Eurycomanone, the major quassinoid in Eurycoma longifolia root (comprising the largest single bioactive fraction in standardized extracts), has demonstrated direct effects on testicular steroidogenesis in preclinical models. Low et al. (2013) showed that eurycomanone increased testosterone production in rat Leydig cells in a dose-dependent manner by inhibiting aromatase (CYP19) — the enzyme that converts testosterone to estradiol — thereby reducing estrogenic conversion and preserving testosterone levels. At higher concentrations, phosphodiesterase (PDE) inhibition was also observed, which may contribute to enhanced intracellular cAMP signaling in steroidogenic cells.

4. CYP17 enzyme activation via eurypeptides: The bioactive peptide complex has been reported to activate CYP17 (17-alpha-hydroxylase/17,20-lyase), a key enzyme in the steroidogenic pathway that converts pregnenolone to DHEA and progesterone to androstenedione — both upstream precursors to testosterone. This mechanism would increase substrate availability for testosterone synthesis rather than acting on the final conversion step.

5. Aromatase inhibition: In addition to the eurycomanone-mediated aromatase inhibition observed in cell studies, the overall extract may reduce peripheral aromatization of testosterone to estradiol. This would theoretically shift the testosterone-to-estrogen ratio in favor of testosterone, though clinical data on estradiol changes are inconsistent (Chan et al. 2021 actually found increased estradiol alongside increased testosterone).

6. Glycosaponin and squalene derivative contributions: Glycosaponins (constituting up to 40% of the standardized extract by weight) and squalene-type triterpenes (eurylene, longilene peroxide) contribute to the overall bioactivity profile, though their specific mechanistic contributions to testosterone modulation are less well characterized. Glycosaponins may influence cell membrane dynamics and steroid receptor accessibility.

Mechanistic Caveats

• The eurypeptide hypothesis, while widely cited, is based primarily on in vitro and preclinical data. The precise molecular mechanism by which eurypeptides reduce SHBG binding affinity in vivo has not been fully elucidated.
• The relative contributions of eurypeptides, quassinoids (eurycomanone), glycosaponins, and other constituents to the overall clinical effect remain unclear. The standardized extract is a complex mixture, and synergistic interactions between compound classes are likely.
• The clinical effect sizes for testosterone modulation are modest (typically 15-37% increases in favorable studies) and are most pronounced in populations with suboptimal baseline levels (stressed individuals, aging men, hypogonadal men). In young, healthy, eugonadal males, effects may be smaller or absent.
• [UNCERTAIN] Whether the mechanism primarily involves increased testosterone production, decreased testosterone clearance, or altered binding protein dynamics (or a combination of all three) has not been definitively resolved by current research.

Clinical Evidence Summary

Clinical evidence for Eurycoma longifolia consists of multiple randomized controlled trials and open-label studies, with the most robust evidence coming from trials using standardized water extracts (Physta/LJ100) at doses of 200-400 mg/day.

Testosterone and Hormonal Parameters

Stress Hormones and Mood

Sexual Function and Fertility

Ergogenic Effects

Systematic Review and Meta-Analysis

Evidence Limitations

• Sample sizes are small to moderate across all RCTs (n=25-109, most under 65). The largest single trial is Ismail et al. (2012) with 109 subjects, and the Chinnappan et al. (2021) multicentre trial with 105 subjects.
• Industry involvement: Many key studies were funded by or conducted in collaboration with Biotropics Malaysia (manufacturer of Physta) or HP Ingredients (marketer of LJ100). While this does not invalidate the findings, independent replication by groups without commercial ties would strengthen the evidence base.
• Geographic concentration: The majority of clinical research has been conducted in Malaysia or by Malaysian-affiliated research groups. Broader international replication is needed.
• Duration: Most trials are 4-12 weeks in duration. The longest published RCT is the 6-month Sazali et al. (2021) trial. Long-term safety and efficacy data beyond 6 months are essentially absent.
• Population specificity: Effects appear most pronounced in populations with suboptimal baseline testosterone (stressed individuals, aging men, diagnosed hypogonadism). Evidence in young, healthy, eugonadal males is more limited, and the Chan et al. (2021) trial, while positive, used a higher dose (600 mg/day) and a very short duration (2 weeks).
• Heterogeneity in preparations: Although most studies used the standardized Physta/LJ100 extract, some older studies and traditional use data involve non-standardized root preparations, making cross-study comparison difficult.
• No head-to-head comparisons with pharmaceutical testosterone replacement therapy (TRT) or other testosterone-modulating herbs (ashwagandha, fenugreek) have been published.

Safety Profile

General Assessment

Tongkat Ali, particularly the standardized hot-water extract (Physta/LJ100), has a favorable short-term safety profile based on available clinical trial data. No serious adverse events have been reported in published RCTs at doses of 200-400 mg/day for up to 6 months. The Malaysian Ministry of Health has approved the herb as a traditional medicine, and long historical use in Southeast Asian traditional medicine supports general safety at traditional dose levels.

However, long-term safety data (beyond 6 months) from controlled studies are lacking, and the 2021 EFSA novel food assessment raised concerns about potential genotoxicity at extremely high doses in animal models, introducing an element of regulatory caution in the European context.

Contraindications

• Hormone-sensitive cancers (breast, prostate, endometrial): As a phytoandrogenic agent that may modulate testosterone, estradiol, and SHBG levels, Tongkat Ali should be avoided by individuals with hormone-sensitive malignancies. While George & Henkel (2014) noted cytotoxicity against prostate cancer cells in vitro, the clinical implications are unclear, and a precautionary contraindication is appropriate.
• Cardiac conditions (theoretical): Some traditional sources and safety databases note theoretical concerns for individuals with cardiac arrhythmias or heart disease, though no clinical cases of cardiac adverse events have been documented. This remains a theoretical precaution pending further data.
• Liver disease: While clinical trials have not shown hepatotoxicity (no significant changes in ALT, AST, GGT, or bilirubin), isolated case reports in the LiverTox database (NCBI) have described clinically apparent liver injury attributed to Tongkat Ali in bodybuilders — though confounding factors (polypharmacy, adulteration of commercial products) limit the interpretability of these reports.
• Kidney disease: Rare case reports suggest potential renal effects (acute tubular necrosis), though these are poorly documented and likely involved non-standardized or adulterated products.
• Immunocompromised individuals: Some sources recommend caution due to immunomodulatory properties observed in preclinical models.

Drug Interactions

• No clinically documented drug interactions have been reported in published literature for the standardized water extract (Physta/LJ100).
• Theoretical — CYP3A4 and P-glycoprotein: Some in vitro and review evidence suggests potential interactions via CYP3A4 inhibition and P-glycoprotein modulation. This is clinically unconfirmed but warrants caution with medications that are CYP3A4 substrates (e.g., certain statins, calcium channel blockers, immunosuppressants, some antiretrovirals).
• Theoretical — Antidiabetic agents: Preclinical data suggest mild antihyperglycemic effects. Additive hypoglycemia is theoretically possible with insulin or oral antidiabetic drugs, though no clinical cases have been reported.
• Theoretical — Anticoagulants: Some in vitro data suggest mild anticoagulant properties. Caution with warfarin or other anticoagulants is prudent.
• Testosterone replacement therapy (TRT) and anabolic steroids: Co-administration with exogenous androgens is not recommended due to unpredictable additive hormonal effects.

Side Effects (at Recommended Doses)

• Common: Generally well tolerated. Mild gastrointestinal discomfort (nausea, stomach pain, diarrhea) is the most frequently reported side effect, though incidence in clinical trials is low and usually comparable to placebo.
• Uncommon: Insomnia or restlessness (reported anecdotally, possibly related to increased energy or testosterone effects); headache; mild irritability.
• Rare: Allergic skin reactions (rash); elevated body temperature (anecdotal).
• No consistent hepatotoxicity signal in clinical trials at doses of 200-400 mg/day for up to 6 months. Liver function markers (ALT, AST, GGT, bilirubin) have remained within normal limits in monitored studies.

Pregnancy and Lactation

• Pregnancy: Category X — Contraindicated. There are no controlled studies of Eurycoma longifolia in pregnant women. Given the herb’s hormonal activity (testosterone modulation, potential aromatase inhibition, effects on the HPA axis), use during pregnancy is contraindicated due to the risk of adverse effects on fetal hormonal development. The EFSA 2021 assessment explicitly excluded pregnant and lactating women from the target population.
• Lactation: Avoid. No data on excretion into breast milk. Given hormonal activity, avoidance during breastfeeding is recommended.

Toxicology Notes

• Acute toxicity (animal): LD50 in mice for the aqueous root extract has been reported as greater than 3,000 mg/kg orally, indicating low acute toxicity.
• Subchronic toxicity (animal): 28-day and 90-day repeated dose studies in rats at doses up to 1,000 mg/kg/day have not shown significant adverse effects on organ function, hematology, or histopathology.
• Genotoxicity concern: The 2021 EFSA Panel assessment identified potential DNA damage (genotoxicity) in stomach and duodenal tissues at a very high dose of 2,000 mg/kg body weight in animal models. This dose is approximately 200-300 times the typical human supplemental dose on a per-kg basis and well beyond any clinically used dosage. The panel requested additional genotoxicity data from the applicant before approving the extract as a novel food. This finding does not directly apply to typical supplemental use but introduces a note of regulatory caution.
• Heavy metal and contaminant risk: As with many Southeast Asian botanical products, quality control is critical. Adulterated or non-standardized products may contain heavy metals (lead, mercury), undeclared pharmaceutical agents (sildenafil, tadalafil), or microbial contaminants. Use of standardized, GMP-certified extracts (Physta/LJ100) mitigates this risk.

Clinical Dosage

Standardized Water Extract (Physta / LJ100) — Most Clinically Studied Form

Non-Standardized Root Preparations (Traditional Use)

Administration Guidance

• Timing: Typically taken in the morning or early afternoon. Some users report mild energizing or stimulating effects; late-evening dosing may contribute to insomnia in sensitive individuals.
• Duration: Clinical effects on testosterone parameters are typically observed after 2-4 weeks of continuous use (Chinnappan et al. 2021 showed significant changes at week 2 for the 200 mg dose). The longest published RCT is 6 months (Sazali et al. 2021). Cycling protocols (e.g., 5 days on / 2 days off, or 8 weeks on / 2 weeks off) are commonly recommended by practitioners but are not based on published clinical evidence.
• With or without food: No strong clinical guidance. Some practitioners recommend taking with food to minimize GI discomfort.
• Product quality: Given the risk of adulteration in the Tongkat Ali supplement market, use of branded, third-party-tested, standardized extracts (Physta, LJ100) is strongly recommended. The Malaysian Standard MS 2409:2011 provides a quality benchmark.

Sources

Systematic Reviews and Meta-Analyses

• Leisegang K, Finelli R, Sikka SC, Panner Selvam MK. Eurycoma longifolia (Jack) improves serum total testosterone in men: a systematic review and meta-analysis of clinical trials. Medicina (Kaunas). 2022;58(8):1047. doi:10.3390/medicina58081047. PMID: 36013514
• Thu HE, Mohamed IN, Hussain Z, Jayusman PA, Shuid AN. Eurycoma longifolia as a potential adoptogen of male sexual health: a systematic review on clinical studies. Chin J Nat Med. 2017;15(1):71-80. PMID: 28259255

Key Randomized Controlled Trials

• Chinnappan SM, George A, Gota V, Choudhury H. Effect of Eurycoma longifolia standardised aqueous root extract—Physta on testosterone levels and quality of life in ageing male subjects: a randomised, double-blind, placebo-controlled multicentre study. Food Nutr Res. 2021;65:5647. doi:10.29219/fnr.v65.5647. PMID: 34262417
• Talbott SM, Talbott JA, George A, Pugh M. Effect of Tongkat Ali on stress hormones and psychological mood state in moderately stressed subjects. J Int Soc Sports Nutr. 2013;10(1):28. doi:10.1186/1550-2783-10-28. PMID: 23705671
• Ismail SB, Wan Mohammad WMZ, George A, Hussain NHN, Musthapa Kamal ZM, Liske E. Randomized clinical trial on the use of PHYSTA freeze-dried water extract of Eurycoma longifolia for the improvement of quality of life and sexual well-being in men. Evid Based Complement Alternat Med. 2012;2012:429268. doi:10.1155/2012/429268. PMID: 23227105
• Sazali S, Badrin S, Norhayati MN, Idris NS. A 6-month, double-blind, placebo-controlled, randomized trial to evaluate the effect of Eurycoma longifolia (Tongkat Ali) and concurrent training on erectile function and testosterone levels in androgen deficiency of aging males (ADAM). Maturitas. 2021;145:78-85. doi:10.1016/j.maturitas.2020.12.012. PMID: 33541567
• Chan KQ, Stewart C, Chester N, et al. The effect of Eurycoma longifolia on the regulation of reproductive hormones in young males. Andrologia. 2021;53(4):e14001. doi:10.1111/and.14001. PMID: 33559971

Open-Label and Pilot Studies

• Tambi MIBM, Imran MK, Henkel RR. Standardised water-soluble extract of Eurycoma longifolia, Tongkat ali, as testosterone booster for managing men with late-onset hypogonadism? Andrologia. 2012;44(Suppl 1):226-230. doi:10.1111/j.1439-0272.2011.01168.x. PMID: 21671978
• Henkel RR, Wang R, Bassett SH, et al. Tongkat Ali as a potential herbal supplement for physically active male and female seniors—a pilot study. Phytother Res. 2014;28(4):544-550. doi:10.1002/ptr.5017. PMID: 23754792

Pharmacology, Phytochemistry, and Review Articles

• George A, Henkel R. Phytoandrogenic properties of Eurycoma longifolia as natural alternative to testosterone replacement therapy. Andrologia. 2014;46(7):708-721. doi:10.1111/and.12214. PMID: 24386995
• Khanijah O, Ridzuan Noor M, Nurdiana S, et al. Review on a traditional herbal medicine, Eurycoma longifolia Jack (Tongkat Ali): its traditional uses, chemistry, evidence-based pharmacology and toxicology. Molecules. 2016;21(3):331. doi:10.3390/molecules21030331. PMID: 26978330
• Low BS, Das PK, Chan KL. Standardized quassinoid-rich Eurycoma longifolia extract improved spermatogenesis and fertility in male rats via the hypothalamic-pituitary-gonadal axis. J Ethnopharmacol. 2013;145(3):706-714. doi:10.1016/j.jep.2012.11.013. PMID: 23810842
• Ruan J, Li Z, Zhang Y, et al. A multifaceted review of Eurycoma longifolia nutraceutical bioactives: production, extraction, and analysis in drugs and biofluids. ACS Omega. 2022;7(51):47511-47528. doi:10.1021/acsomega.2c06340. PMID: 36591154

Regulatory and Safety Documents

• EFSA Panel on Nutrition, Novel Foods and Food Allergens. Safety of Eurycoma longifolia (Tongkat Ali) root extract as a novel food pursuant to Regulation (EU) 2015/2283. EFSA J. 2021;19(12):e06937. doi:10.2903/j.efsa.2021.6937. PMID: 34938370
• LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Tongkat Ali. National Institute of Diabetes and Digestive and Kidney Diseases; 2023. PMID: 31643590
• Malaysian Standard MS 2409:2011. Phytopharmaceutical aspect of freeze dried water extract from Tongkat Ali roots — Specification
• Escalante G, Barakat A, Groom A, et al. The effect of Tongkat Ali supplementation on body composition in exercise-trained males and females. Appl Sci. 2024;14(11):4372. doi:10.3390/app14114372

Connections

• Maca: Both are non-European men’s health herbs with C-level evidence for sexual function and vitality. A key distinction: maca does NOT alter circulating sex hormone levels and works through the endocannabinoid system (FAAH inhibition), while Tongkat Ali demonstrably raises total and free testosterone through SHBG modulation and HPA axis effects. They represent fundamentally different pharmacological approaches to overlapping clinical indications and are frequently combined in supplement formulations.
• Ashwagandha: Both herbs modulate the HPA axis and cortisol levels. Ashwagandha (KSM-66 and Sensoril extracts) has stronger evidence for anxiolytic effects and cortisol reduction, while Tongkat Ali has more direct evidence for testosterone elevation. Both are used for stress-related hormonal decline and ergogenic purposes. Ashwagandha has a larger and more diverse evidence base overall.
• Fenugreek: Fenugreek (particularly the Testofen extract standardized to furostanol saponins) has been marketed for testosterone support, though its evidence base is modest and its primary European regulatory indications are for appetite and blood glucose. The mechanisms differ significantly: fenugreek’s steroidal saponins may influence androgen metabolism differently than Tongkat Ali’s eurypeptide/quassinoid profile.
• Saw Palmetto: Both herbs are used in men’s health but target different endpoints. Saw palmetto is primarily a 5-alpha-reductase inhibitor used for benign prostatic hyperplasia (BPH), while Tongkat Ali targets testosterone support and stress adaptation. They address different aspects of male hormonal health and are sometimes combined in prostate/testosterone support formulations.
• Nettle Root: Nettle root is relevant to the SHBG discussion — it is traditionally used and has some evidence for binding to SHBG and potentially influencing free testosterone availability, though its primary indication in European phytotherapy is BPH. The SHBG-modulating mechanism provides a conceptual bridge between nettle root and Tongkat Ali pharmacology.
• Broader context: Tongkat Ali represents the growing integration of Southeast Asian traditional medicines into the global evidence-based supplement landscape. Its trajectory — from traditional Malaysian remedy to standardized, clinically studied extract — parallels the path taken by ashwagandha (Ayurvedic tradition) and maca (Andean tradition). The standardization of the Physta/LJ100 extract to specific eurycomanone and glycosaponin content marks a maturation of the evidence base from ethnobotanical anecdote toward reproducible clinical pharmacology.